ArticleDiscover oncology2025
Glutamate promotes triple-negative breast cancer development through IRE1α/XBP1-mediated macrophage polarization: mechanism insights and therapy.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regulatory Mechanisms of XBP1 in Tumorigenesis and Cancer Progression: Challenges and Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Metabolomics-based exploration of the pathogenesis of breast cancer-related fatigue and progress of traditional Chinese medicine intervention.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) is a highly aggressive malignancy associated with early recurrence, metastatic propensity, and poor clinical outcomes, yet its underlying molecular mechanisms remain incompletely elucidated. This study aims to investigate the role of glutamate in promoting macrophage polarization and TNBC progression via the IRE1α/XBP-1 signaling pathway.
methodsThe growth and pathological changes of tumor and the protein expression levels of p-PERK, ATF6, IRE1α, XBP-1, G-CSF, GM-CSF, arginase-1, CD206, iNOS and TNF-α in tumor cells were observed in vivo experiments. The expression levels of IL-6, G-CSF and GM-CSF in MCF-7 cells and MDA-MB-231 cells as well as cell proliferation, migration, invasion and cell viability were observed in vitro experiments.
resultsIn the vivo experiments, compared with common breast cancer tumors and TNBC tumors without overexpressing glutaminase 1 (GLS1), the tumor volume of TNBC with overexpressing GLS1 increased significantly, and the tissue necrosis increased (p < 0.05). After GLS1 overexpression, the levels of P-PERK, ATF6, IRE1α, XBP-1, G-CSF, GM-CSF, arginase-1 and CD206 in TNBC tumors significantly increased, while the levels of iNOS and TNF-α significantly decreased (p < 0.05). In the vitro experiments, compared to MCF-7 cells and MDA-MB-231 cells without the XBP-1 inhibitor toyocamycin, the levels of IL-6, G-CSF, GM-CSF, cell proliferation, migration, invasion ability, and cell viability in MDA-MB-231 cells supplemented with the XBP-1 inhibitor toyocamycin were significantly reduced (p < 0.05).
conclusionsGlutamate can promote macrophage polarization and the development of TNBC by upregulating IRE1α/XBP-1. Targeted inhibition of glutamate metabolism or IRE1α/XBP-1 pathway can effectively block the proliferation of TNBC tumor cells, providing a basis for the study of targeted drugs to treat TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.